IRVINE, Calif., Dec. 5, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that the American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines indicating that chromosomal microarray analysis (CMA) is now recommended as the first-line genetic test in pregnancies showing fetal abnormalities on an ultrasound screen.
Help employers find you! Check out all the jobs and post your resume.
